After the end of yesterday’s trading session the stock price of IntelGenx Technologies Corp. (OTC:IGXT) looks stable at its current level. Unfortunately, even the announced FDA approval could not move IGXT share price for more than a day. 
IGXT closed yesterday with a decline of 4.35% at $0.55, but during the session the price did not fall below $0.54 and the trading volume of 342,612 traded shares was much lower than the average, which suggests that the market is consolidated and a meaningful decrease of the share price may not follow at this point.
Latest news from IntelGenx Technologies has been its financial report for the period ending September 30, 2011. It, however, did not contain any information that could completely change the market attitude towards the company. Also, it seems that the market value of IGXT stock had already reflected the other anticipated news that came out on November 11.
As expected, that day the company announced that the FDA had approved IGXT lead product candidate CPI-300 which is now allowed for patients with Major Depressive Disorder. At the end of the press release, the company states that it is now in active discussion with potential license candidates and expects to have the product launched on the market soon. The share price moved to $0.72 shortly after that, but that did not last for long.
If the FDA approval and a potential commercialization agreement would mean directly a higher share price of IGXT stock is another issue which requires a through research on the company if it is to be considered as a long-term investment.
